Targeting transcription factors for cancer therapy

Area of Science:

• Molecular Biology
• Oncogenesis
• Cancer Research

Background:

• Transcription factors play a critical role in oncogenesis, either through direct mutation or alterations in upstream regulatory proteins.
• This review focuses on four key transcription factors implicated in cancer: Signal Transducer and Activator of Transcription 3 (Stat3), Stat5, Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and Hypoxia-Inducible Factor 1 (HIF-1).

Purpose of the Study:

• To review the evidence linking Stat3, Stat5, NF-kappaB, and HIF-1 to cancer development.
• To examine therapeutic strategies aimed at targeting these transcription factors for cancer intervention.

Main Methods:

• Review of existing scientific literature on transcription factors and oncogenesis.
• Analysis of therapeutic approaches including peptidomimetics, antisense oligonucleotides, small molecule inhibitors, and G-quartet oligonucleotides.
• Discussion of therapeutic targeting at the levels of activation, translocation, and DNA binding.

Main Results:

• Established roles for Stat3, Stat5, NF-kappaB, and HIF-1 in various stages of cancer development.
• Demonstrated potential of therapeutic interventions targeting these transcription factors in preclinical models.
• Exploration of diverse mechanisms for inhibiting transcription factor activity.

Conclusions:

• Transcription factors are pivotal in cancer, presenting viable therapeutic targets.
• Targeted inhibition strategies offer promising avenues for novel cancer treatments.
• Further research and application in in vitro and in vivo models are essential for clinical translation.